CNBC's Brian Sullivan reports on President Trump's commentary about Venezuela's oil industry during his meeting with oil executives at the White House.

Shares of CapsoVision, Inc. (NASDAQ: CV - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $12.39, but opened at $10.85. CapsoVision shares last traded at $11.05, with a volume of 7,782 shares trading hands. Analysts Set New Price Targets Several equities research analysts have recently weighed in

CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.

CapsoVision, Inc. (NASDAQ: CV - Get Free Report)'s share price traded down 6.5% on Friday. The stock traded as low as $12.90 and last traded at $12.98. 11,088 shares were traded during trading, a decline of 93% from the average session volume of 163,197 shares. The stock had previously closed at $13.88. Wall Street Analysts

CapsoVision's (NASDAQ: CV - Get Free Report) lock-up period will expire on Monday, December 29th. CapsoVision had issued 5,500,000 shares in its initial public offering on July 2nd. The total size of the offering was $27,500,000 based on an initial share price of $5.00. After the expiration of CapsoVision's lock-up period, company insiders and major shareholders

CapsoVision shares surged in after-hours trading following the appointment of David Garcia as senior vice president of finance.

SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on Thursday, December 4, 2025 in New York City.

Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET

- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market.